Restrictive Transfusion StratEgy Adjusted by SvO2 During Cardiac Surgery

The goal of the clinical trial is to evaluate whether a restrictive transfusion strategy adjusted by SvO2 during the perioperative period of cardiac surgery may reduce the incidence of red blood cell transfusion. Adult patients operated on cardiac surgery will be randomly allocated into two groups, one receiving standard restrictive transfusion, the other receiving SvO2 adjusted restrictive transfusion.The proportion of patients transfused will be compared between the 2 groups.

Inclusion Criteria:Aged above 18 years and under 85 yearsSigned informed consent formOperated on elective, on-pump cardiac surgery for:Coronary artery bypass graft (CABG); Aortic, mitral or tricuspid valve (replacement or repair); Ascending aorta;Left ventricle assistance device (LVAD)Operated on urgent on-pump cardiac surgery for : CABG;Endocarditis;Aortic dissection; Heart transplantationSubjects must be covered by public health insuranceExclusion Criteria:Patient with no central venous catheter inserted in the superior vena cavaPregnant or breast feeding patientSubject unable to read or/and writeParticipation in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening dateMedical history of heparin-induced thrombocytopenia contraindicating heparin use during surgeryPersons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric care and persons admitted to a health or social establishment for purposes other than research